Status:
COMPLETED
Right Ventricular Function in Patients Taking Carfilzomib
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ...
Detailed Description
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ...
Eligibility Criteria
Inclusion
- Patients treated for multiple myeloma with carfilzomib
- Patients with echocardiogram before and under treatment.
Exclusion
- /
Key Trial Info
Start Date :
April 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06568952
Start Date
April 30 2024
End Date
July 30 2024
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Simon VALENTIN
Nancy, France, 54500